Liquid Trace™: Solid Tumor Profile
Use
Liquid Trace™ takes a comprehensive approach in analyzing all solid tumors through a combination of DNA and RNA sequencing. It is designed to detect chromosomal abnormalities, gene amplifications, and specific fusions such as ALK, ROS1, RET, NTRK1/2/3, among others. It also profiles various mutations and gene expressions including BRAF, PD-L1, MET exon 14 skipping, and more. For patients, it provides critical insight for monitoring therapeutic response and for potential clinical trial matching.
Special Instructions
Not provided.
Limitations
The test is dependent on the quality and quantity of DNA/RNA in patient samples, which can impact the ability to detect certain variants or gene expressions. Also, the stability of RNA is limited to 48-72 hours post-collection, necessitating prompt processing.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
8-10 mL
Minimum Volume
Not provided
Container
EDTA tube (preferred)